GlassScriptPhysician profile
James Anthony Richter
NPI 1821202821
$6,556.71
in general payments reported to CMS, 2019-2025
37 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $128 · 2021: $619 · 2022: $1,596 · 2023: $1,324 · 2024: $1,148 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,009.95 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.55 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $512.58 | 2019-2025 | |
| Celgene Corporation | $429.69 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $283.02 | 2019-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $272.48 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $234.14 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $227.96 | 2021-2024 | Linzess |
| Genzyme Corporation | $200.89 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $197.32 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $175.63 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $154.80 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $149.74 | 2022-2025 | Rebyota |
| Lilly USA, LLC | $148.65 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $140.72 | 2024-2025 | Vowst, Zenpep |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $121.80 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $84.69 | 2019-2024 | Ocaliva |
| Daiichi Sankyo INC. | $81.48 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $76.14 | 2024-2025 | Dupixent |
| Medtronic, INC. | $61.11 | 2022 | |
| Mylan Institutional INC. | $41.94 | 2023 | Hulio |
| Organon LLC | $41.45 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $40.10 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $29.62 | 2021-2023 | Advanix Biliary |
| Vivus LLC | $25.36 | 2021 | |
| Mallinckrodt Hospital Products INC. | $23.19 | 2025 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $16.68 | 2021 | |
| W. L. Gore & Associates, INC. | $16.42 | 2021 | |
| Fresenius Kabi USA, LLC | $16.41 | 2023 | |
| Redhill Biopharma INC. | $15.45 | 2021 | |
| Ethicon US, LLC | $15.42 | 2021 | |
| Enterra Medical, INC. | $14.34 | 2023 | |
| Amgen INC. | $14.01 | 2022 | |
| Endo Pharmaceuticals INC. | $13.54 | 2019 | |
| Allergan, INC. | $12.53 | 2020 | |
| Romark Laboratories, Lc | $11.52 | 2019 | |
| Intra-Sana Laboratories | $10.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.